Key result
Glycoprotein IIb/IIIa inhibitors are potent antiplatelet agents for acute coronary syndromes, though their safety, cost-effectiveness, and optimal patient selection require further investigation.
Glycoprotein IIb/IIIa inhibitors represent a breakthrough in the treatment of acute coronary syndromes, though further investigation is needed regarding safety, cost-effectiveness, and risk stratification.
GP IIb/IIIa inhibitors warrant cautious ACS use pending safety data; leaves open optimal selection and cost-effectiveness.
Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.
No takes yet. Share an insight, caveat, or question.
FRANCIS et al. (2000) studied this question. Glycoprotein IIb/IIIa inhibitors are potent antiplatelet agents for acute coronary syndromes, though their safety, cost-effectiveness, and optimal patient selection require further investigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: